SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Abgenix, Inc. (ABGX)
An SI Board Since December 1998
Posts SubjectMarks Bans
590 38 0
Emcee:  Henry Niman Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
365<i>We believe AMG 162 represents a potential billion dollar product....<nigel bates-9/16/2004
364SSB's take on AMG 162, from reading ACR abstracts recently released, with thtuck-9/16/2004
363AMG 162 Phase 3 Studies for Postmenopausal Osteoporosis and Treatment-Induced BoIcebrg-9/5/2004
362FREMONT, Calif., Aug 13, 2004 (BUSINESS WIRE) -- Abgenix, Inc. (ABGX, Trade) annsjemmeri-8/13/2004
361Erik, I hope you were positioned for the current correction in the biotechnologyQualified Opinion-8/7/2004
360>>Someone - Erik>> I am on the road travelling Germany/Holland and Icebrg-8/4/2004
359Wilder, That's kind of what I was afraid of. I was looking at best case JFitnich-8/4/2004
358I think you make a lot of sense while also making generous assumptions. I havenkeokalani'nui-8/3/2004
357To all and anyone, I’ve had a chance to look through a couple of the reports fJFitnich-8/3/2004
356IMCL major problems with its chemo-combo patent are novelty and non-obviousness.keokalani'nui-8/3/2004
355>>Isn't the IMCL patent claim anti-EGFr in combo with chemo? Isn'ttuck-8/3/2004
354MZ is in Croatia. Hope he's having a good vacation. Isn't the IMCL patscaram(o)uche-8/3/2004
353I have been trying to get a handle on ABX-EGF's possible cost advantage verstuck-8/1/2004
352I have been trying to get a handle on ABX-EGF's possible cost advantage verstuck-8/1/2004
351The Rowinsky study is a now a full text freebie: jco.org As is an editorial dituck-8/1/2004
350GS: ABGX(IL/N) Q2 update - Panitumumab (ABX-EGF) and pipeline key drivers 52-Wemopgcw-7/28/2004
349Revenues on the high side of estimates, but expenses even higher, it would appeatuck-7/27/2004
348Agensys Signs Collaboration and License Agreement with Genentech SANTA MONICA, nigel bates-7/22/2004
347Abgenix names Ringo as new president, CEO Tuesday July 20, 5:13 pm ET LOS ANGELIcebrg-7/20/2004
346[ABX-EGF -- PII Renal Cancer] >>JCO Early Release, published online aheadtuck-7/15/2004
345SSB: Abgenix (ABGX, Hold, Speculative) Reporting date: Tuesday, July 27th, aftmopgcw-7/9/2004
344<i>No human antihuman antibodies were detected</i> Would that have nigel bates-6/23/2004
343JCO Early Release, published online ahead of print Jun 21 2004 Journal of ClinicBiomaven-6/22/2004
342Joe, >>Do you have any insight into intellectual properties rights to antIcebrg-6/20/2004
341Erik--Do you have any insight into intellectual properties rights to anti-CTLA4 JOEBT1-6/19/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News